Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Ebersberg

11 clinical trials in Ebersberg, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Ebersberg at a glance
11
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

11 trials in Ebersberg

Open in trial search

Agitation+1

Recruiting

A study to evaluate the safety and effectiveness of dextromethorphan, deramciclane fumarate, and deramciclane in treating agitation in people with Alzheimer's disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dextromethorphan Hydrobromide

Phase 2a Study of Safety, Tolerability and Efficacy of Intranasal Cenegermin in Adults with Moderate to Severe Subacute Traumatic Brain Injury

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Torticollis

Recruiting

Study on IPN10200 for Treating Cervical Dystonia in Adults

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Clostridium Botulinum, Neurotoxin Serotype A/B
  • Sponsor:Ipsen Innovation

Parkinson's disease

Not yet recruiting

A study to test if BHV-8000 is effective and safe for adults with early Parkinson's disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ioflupane (123I)
  • Sponsor:Biohaven Therapeutics Ltd.

Parkinson's disease

Not yet recruiting

A Randomized Trial of lu af28996 dh1 to Reduce Motor Fluctuations in Adults with Parkinson’s Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:H. Lundbeck A/S

Migraine

Not recruiting

Study on Botulinum Toxin Type A for Preventing Chronic Migraine in Adults

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Botulinum Toxin Type A - Haemagglutinin Complex
  • Sponsor:Ipsen Innovation

Parkinson's disease

Not recruiting

Comparing Skin Adhesiveness of a New Rotigotine 12 mg/24 h Transdermal Patch Versus Standard Treatment in Patients with Parkinson's Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rotigotine
  • Sponsor:Luye Pharma Switzerland AG

Study of Amlenetug for Patients with Multiple System Atrophy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amlenetug
  • Sponsor:H. Lundbeck A/S

Study on Palbociclib and Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib
  • Sponsor:ABCSG GmbH

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:AstraZeneca AB

Neoplasm malignant

Not recruiting

Study on Atezolizumab and Chemotherapy for Patients with Triple-Negative Breast Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:NSABP Foundation Inc.

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Ebersberg

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on triple-negative breast cancer treatment, evaluating the effectiveness of combining immunotherapy with conventional chemotherapy approaches.

  • Neoadjuvant Chemotherapy Studies
  • Immunotherapy Integration
  • Event-free Survival Assessment

Research aims to enhance treatment outcomes through targeted therapeutic combinations.

02 Genetic-Based Treatment

Studies examining treatment efficacy in patients with BRCA mutations, specifically targeting high-risk HER2-negative breast cancer cases.

  • Adjuvant Therapy Development
  • Invasive Disease Management
  • Targeted Treatment Approaches

Focused on improving survival rates through genetically-informed treatment strategies.

03 Hormone Receptor Research

Investigation of advanced treatment protocols for HR+/HER2- early breast cancer, combining endocrine therapy with innovative therapeutic agents.

  • Long-term Endocrine Therapy
  • Combination Treatment Protocols
  • Disease-free Survival Studies

Evaluating enhanced treatment strategies for hormone-responsive breast cancers.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.